Vanessa Paddy
Acute Care · Elizabethtown, KYNPI 1396805271
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,242 of the $8,481 with a category attached, or 85.4%. 27 manufacturers reported payments, led by Medtronic at 31.5% of the total. 2025 is the largest year on record at $2,287, 5.3 times the $429 reported in 2021. Among acute care clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $28.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Lilly USA, LLC$1K
- Novo Nordisk$553
- BETA Bionics, Inc.$462
- Corcept Therapeutics$413
- Sanofi-aventis U.S. LLC$377
- plus $3K from 21 others
What the payments were for
- Travel & lodging$1,23615%
- Food & beverage$7,24285%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 51 | $2,673 |
| Lilly USA, LLC | 46 | $1,010 |
| Novo Nordisk | 19 | $553 |
| BETA Bionics, Inc. | 10 | $462 |
| Corcept Therapeutics | 19 | $413 |
| Sanofi-aventis U.S. LLC | 14 | $377 |
| Insulet Corporation | 23 | $364 |
| Dexcom, Inc. | 4 | $355 |
| Averitas Pharma Inc. | 14 | $319 |
| Bayer | 18 | $305 |
| Tandem Diabetes Care, Inc. | 14 | $295 |
| Boehringer Ingelheim | 15 | $247 |
| Abbott | 17 | $243 |
| AstraZeneca | 6 | $196 |
| Cequr Corporation | 2 | $154 |
| Xeris Pharmaceuticals, Inc. | 6 | $131 |
| Mannkind Corporation | 4 | $93 |
| Novartis | 5 | $79 |
| Nevro Corp. | 2 | $42 |
| Ascensia Diabetes Care US Inc. | 2 | $27 |
| Amphastar Pharmaceuticals, Inc. | 2 | $27 |
| Sequel Med Tech, LLC | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $21 |
| TG Therapeutics, Inc. | 1 | $19 |
| Lifescan, Inc. | 1 | $19 |
| Globus Medical | 1 | $17 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,118
- iLet Bionic Pancreas$913
- MINIMED 780G$396
- DEXCOM G6 TRANSMITTER$219
- TZIELD$126
- FARXIGA$125
- Ozempic$125
- Wegovy$124
- MOUNJARO$114
- Korlym$109
- iLet Insulin Infusion Kit Inset$108
- iLet Insulin Infusion Kit Contact Detach$108
- LYUMJEV$107
- DEXCOM G7 GSS (161)$106
How this compares
$8,481 in reported general payments places this provider in the 95th percentile of 319 acute care providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 280 | $347,373 |
| MounjaroTirzepatide | 234 | $277,053 |
| TrulicityDulaglutide | 163 | $207,097 |
| JardianceEmpagliflozin | 192 | $188,134 |
| JanuviaSitagliptin Phosphate | 212 | $178,052 |
| FarxigaDapagliflozin Propanediol | 145 | $150,756 |
| Tresiba Flextouch U-200Insulin Degludec | 79 | $124,674 |
| Humalog Kwikpen U-200Insulin Lispro | 50 | $124,448 |
| Tresiba Flextouch U-100Insulin Degludec | 171 | $121,074 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 74 | $62,508 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $56,147 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 206 | $44,778 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 57 | $41,897 |
| Novolog FlexpenInsulin Aspart | 118 | $39,737 |
| TradjentaLinagliptin | 47 | $35,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,010 | $515,400547 claims |
| Novo NordiskOzempic, Novolog | $553 | $368,125355 claims |
| Boehringer IngelheimJardiance, Tradjenta | $247 | $223,334239 claims |
| MerckJanuvia, Janumet, Janumet Xr | $15 | $201,791239 claims |
| AstraZenecaFarxiga | $196 | $150,756145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 319 acute care providers in Kentucky.
Other acute care in Elizabethtown
- Shannon AtkinsonBowling Green$63K
- Billie WaltersLexington$20K
- Audra MarcumLexington$14K
- Holly ChitwoodLexington$10K
- Baylee KnoxGlasgow$8K
- Katherine BeanOwensboro$7K
- Anna BayesAshland$7K
- Brittany ShortAshland$6K
- Chadwick HuntLexington$6K
- Amber MaynardMurray$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.